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Objective: To better understand Aeromonas-involved polymicrobial bacteremia (AIPMB).
Materials and Methods: We conducted a retrospective analysis of patients with AIPMB admitted to three
large referral hospitals in Taiwan between 2001 and 2008.
Results: Of a total of 62 patients with AIPMB, 22 had healthcare-associated infection and 40 had
community-acquired infection. Enterobacteriaceae was the most common concurrent pathogen (82%).
The leading underlying diseases/conditions in the affected patients were solid cancers (45%), recent
gastric acid suppressant therapy (39%) and liver cirrhosis (26%). More than 95% of the Aeromonas isolates
were susceptible to an aminoglycoside, a third- or fourth-generation cephalosporin, imipenem or
ciproﬂoxacin. Antibiotic susceptibilities did not signiﬁcantly differ between Aeromonas isolates in
patients with healthcare-associated AIPMBs and those in patients with community-acquired AIPMBs.
Coinfection with Enterobacteriaceae occurred more commonly in community-acquired AIPMB (93% vs.
64%; p¼ 0.012).
Conclusions: AIPMB occurred commonly in patients with liver cirrhosis, solid cancers or recent gastric
acid suppressant therapy. Enterobacteriaceae were the most common concurrent pathogens. Similar
antibiotic proﬁles were found in Aeromonas isolates of healthcare-associated and community-acquired
AIPMBs.
Copyright  2011, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
The proportion of cases of bacteremia involving more than one
species has ranged from 5% to 20% over the past 50 years [1]. Pol-
ymicrobial bacteremia is associated with malignancy, surgery and
the placement of central venous catheters [1]. The mortality in
patients with polymicrobial bacteremia is approximately twice that
of patients with monomicrobial bacteremia [2e4].
Aeromonas, a member of the Aeromonadaceae family, is associ-
ated with a variety of human infections including gastroenteritis,
wound infection and septicemia [5e8]. Aeromonas infection is
mainly acquired from the environment, especially contaminatedses, Department of Medicine,
in-Sheng Road, Dalin, Chiayi,
ddhist Compassion Relief Tzu Chiwater. In previous studies, there have been high proportions of
polymicrobial infection where Aeromonas spp. have been involved
in infections of the bloodstream [9e14]. No study has yet delin-
eated the clinical picture of Aeromonas-involved polymicrobial
bacteremia (AIPMB), possibly because of a lack of sufﬁcient cases in
a single healthcare institution. We therefore conducted a retro-
spective multicenter study of AIPMB.
2. Materials and methods
This is a retrospective study of patients diagnosed with AIPMB
admitted to Buddhist Tzu Chi General, Buddhist Dalin Tzu Chi
General and Buddhist Taipei Tzu Chi General Hospitals in Taiwan
between January 2001 and November 2008. Patient data, clinical
and laboratory information were retrieved from the medical charts
of the patients included in the study.
An AIPMB was deﬁned as the simultaneous growth of an Aero-
monas spp. and at least one other microbe from the blood culture ofFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Comparisons of clinical characteristics between healthcare-associated and
community-acquired Aeromonas-involved polymicrobial bacteremias.
Variable Polymicrobial Aeromonas
bacteremia
p
Healthcare-
associated
N¼ 22
Community-
acquired
N¼ 40
Age 65 y, n (%) 7 (32) 24 (60) 0.063
Male, n (%) 17 (77) 16 (40) 0.011
Enterobacteriaceae coinfectiona, n (%) 14 (64) 37 (93) 0.012
Underlying disease/condition
ESRD, n (%) 0 (0) 2 (5) 0.535
Recent intra-abdominal surgery, n (%) 4 (18) 8 (20) 1.000
Solid cancer, n (%) 13 (59) 15 (38) 0.171
Diabetes mellitus, n (%) 5 (23) 8 (20) 1.000
Liver cirrhosis, n (%) 6 (27) 10 (25) 1.000
Neutropenia, n (%) 2 (9) 1 (3) 0.285
Gastric acid suppressant therapy, n (%) 10 (45) 14 (35) 0.592
Laboratory and clinical features
Thrombocytopenia, n (%) 11 (50) 20 (50) 1.000
Leukocytosis, n (%) 8 (36) 15 (38) 1.000
Fever, n (%) 17 (77) 28 (70) 0.751
Diarrhea, n (%) 2 (9) 1 (3) 0.285
Shock, n (%) 11 (50) 16 (40) 0.623
Abdominal pain, n (%) 5 (23) 12 (30) 0.751
Acute renal failure, n (%) 8 (36) 7 (18) 0.177
Acute respiratory failure, n (%) 4 (18) 7 (18) 1.000
APACHE II score 20, n (%) 7 (32) 11 (28) 0.947
Death due to sepsis, n (%) 7 (32) 12 (30) 1.000
Abbreviations: APACHE¼ acute physiology and chronic health evaluation,
ESRD¼ end-stage renal disease.
a See Table 2 for details.
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the patient died of unrelenting sepsis within 7 days after blood was
sampled for culture where the culture was positive for Aeromonas
species and one or more other microbes.
AnAIPMBwasconsideredhealthcare-associated if theAeromonas
isolatewas obtained from blood sampled72 hours after admission
to the hospital in a patient who had been asymptomatic upon
admission, or in a patient who had received antineoplastic chemo-
therapywithin thepast2weeks, regardless of his orher symptomsat
admission [15]. Acute respiratory failure was deﬁned as the ratio of
arterial oxygen tension (PaO2) to fractional inspired oxygen (FiO2)
<200 [16]. The severity of the AIPMB was assessed using the Acute
Physiology and Chronic Health Evaluation II (APACHE II) score less
than 72 hours after the development of sepsis [17].
Gastric acid-suppressant therapy was deﬁned as the use of
a proton-pump inhibitor or a histamine H2 blocker for 7 days
within 4 weeks before the emergence of an AIPMB.
2.1. Species identiﬁcation and antimicrobial susceptibility
Detection of bacterial growth from blood specimens was per-
formed using the BACTEC 9240 blood culture system (BD Diag-
nostic Instrument Systems, Spark, MD, USA). Aeromonas species
(Gram-negative bacilli) were identiﬁed by a positive oxidase test,
growth on MacConkey agar, no growth on thiosulfate-citrate-bile-
sucrose agar, and resistance to 150 mg vibriostatic compound O/
129 [5,18]. Isolates were further conﬁrmed with use of the Vitek II
system (BioMérieux, Lyon, France), BD-Phoenix system (BD Diag-
nostic Instrument Systems, Spark, MD, USA) or API-20NE system
(BioMérieux Marcy-I’Etoile, France). Additional tests, such as
esculin hydrolysis, gas production from glucose, Voges-Proskauer
reaction, ornithine decarboxylase and arginine dihydrolase
production, were performed for the identiﬁcation of bacterial
species as necessary [5,18].
In vitro antimicrobial susceptibilities of Aeromonas isolates were
tested using the Kirby-Bauer disk-diffusion method or automated
methods (Vitek II system or the BD-Phoenix system). All of the
methods tested for gentamicin, amikacin, cefazolin, ceftriaxone,
ciproﬂoxacin, piperacillin/tazobactam and imipenem. The BD-
Phoenix system also ran tests including aztreonem. In the disk-
diffusion method, antibiotics selected for testing also included
cefmetazole, cefuroxime, ceftazidime, cefpirome and aztreonam.
There were, however, some differences in the antibiotics selected
for different Aeromonas isolates tested using the disk-diffusion
method. The susceptibility breakpoints in the disk diffusion
method were in accordance with those of the National Committee
for Clinical Laboratory Standards for Enterobacteriaceae [19], while
the susceptibility breakpoints in the automated methods were in
accordance with those recommended by the Clinical and Labora-
tory Standards Institute M45-A [20].
2.2. Statistical analyses
The Chi-square test or Fisher’s exact test was used to compare
nominal data using the SPSS software package, version 11.0 (SPSS
Inc, Chicago, IL, USA). A two-tailed p value of 0.05 was considered
statistically signiﬁcant.
3. Results
Of a total of 62 patients [mean age 62 years (range: 24e90
years); males: 33/62] with AIPMB, 22 had healthcare-associated
infection and 40 had community-acquired infection. Four patients
presented with necrotizing fasciitis, one with acute cholangitis and
the others with primary bacteremia. Fifty-one patients (82%) hadEnterobacteriaceae coinfection. Solid cancer (45%) was the most
common underlying disease/condition, followed by gastric acid
suppressant therapy (39%) and liver cirrhosis (26%). Forty-ﬁve
patients (73%) presented with fever, 31 (50%) with thrombocyto-
penia and only 23 (37%) with leukocytosis. Eighteen (29%) patients
had very severe disease (APACHE II score 20) and the overall
mortality rate of AIPMBwas 31% (19/62). The clinical characteristics
of healthcare-associated and community-acquired AIPMBs are
detailed in Table 1. The ratios of male gender and Enterobacteriaceae
coinfection were signiﬁcantly higher in community-acquired
AIPMB than in healthcare-associated APIMB.
The concurrent pathogens for healthcare-associated and
community-acquired AIPMBs are listed in Table 2. In community-
acquired infection, Escherichia coli (23/40, 58%) was most
commonly found, followed by Klebsiella spp. (9/40, 23%) and
Enterobacter spp. (5/40, 13%). In healthcare-associated infection,
Klebsiella spp. (5/22, 23%) were most frequently found, followed
by Enterobacter spp. (5/22, 23%) and Acinetobacter spp. (5/22, 23%).
The in vitro antimicrobial susceptibilities of Aeromonas isolates
are listed in Table 3. Therewere 44 Aeromonas isolates tested by the
disk-diffusion method, 12 by the Vitek II system and six by the BD-
Phoenix system. The majority of Aeromonas isolates were suscep-
tible to amikacin, gentamicin, ceftriaxone, ceftazidime, cefpirome,
aztreonam, piperacillin/tazobactam, imipenem and ciproﬂoxacin.
Thirty-nine out of 49 (80%) isolates tested were susceptible to
cefuroxime, 15 of 62 (24%) were susceptible to cefazolin, and 23 of
41 (56%) were susceptible to cefmetazole. Antibiotic susceptibilities
were not statistically different between community-acquired and
healthcare-associated Aeromonas isolates.4. Discussion
In agreement with previous reports [9e14], the majority of
AIPMBs were of primary bacteremia.
Table 2
Concurrent pathogens in patients with Aeromonas-involved polymicrobial
bacteremias.
Concurrent pathogen Healthcare-associated
infection (N¼ 22), (%)
Community-acquired
infection (N¼ 40), (%)
Escherichia coli 3 (14) 23 (58)
Klebsiella spp. 6 (27) 9 (23)
Enterobacter spp. 5 (23) 5 (13)
Proteus spp. 1 (5) d
Serratia spp. d 1 (3)
Morganella morganii d 1 (3)
Citrobacter spp. 1 (5) 2 (5)
Pantoea agglomerans 1 (5) d
Bacteroides spp. 1 (5) 1 (3)
Prevotella oralis 1 (5) d
Coagulase-negative
Staphylococcus
1 (5) d
Streptococci spp. 3 (14) 3 (8)
Enterococcus spp. 3 (14) 2 (5)
Acinetobacter spp. 5 (23) 4 (10)
Stenotrophomonas maltophilia 1 (5) d
Pseudomonas aeruginosa 2 (9) d
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water. They are not considered as commensal organisms in the
human gastrointestinal tract but can be isolated from feces in
asymptomatic people [21]. Of all Aeromonas species, A hydrophila, A
sobria and A caviae are the most common in human infection. In
a mouse model, these three Aeromonas species were found to have
higher colonization rates in colon tissue compared with other
Aeromonas species [22]. Low-pH stomach acid has been reported to
be effective in killing Aeromonas [23]. The high proportion of
patients with AIPMB with prior gastric acid-suppressant therapy in
this study therefore suggests that a higher pHmilieu in the stomach
enhances chances of Aeromonas intestinal colonization. The ﬁnd-
ings that Enterobacteriaceae are the most common concurrent
pathogens for AIPMB in other reports and ours further support the
gastrointestinal tract as the most likely portal of entry for Aero-
monas leading to bacteremia [12e14].
Of all bacteremia cases, a higher proportion of polymicrobial
bacteremia is reported in cancer patients compared with their non-
cancer counterparts [24,25]. Of note, one study found polymicrobial
bloodstream infection in 14% of 2340 patients with an underlying
malignancy and an episode of nosocomial bloodstream infection
[1]. Neutropenia and disruption of the digestive mucosal barrier
caused by antineoplastic therapy, surgery or hypoxia in cancer
patients enables the invasion of various bacteria, especially from
the gut and oropharynx [1,26]. In agreement with these ﬁndings,Table 3
In vitro antibiotic susceptibilities of the Aeromonas isolates.
Antimicrobial agents Susceptible isolates p
Healthcare-associated
infection n/N (%)
Community-acquired
infection n/N (%)
Gentamicin 20/22 (91) 35/40 (88) 1.000
Amikacin 21/21 (100) 38/40 (95) 0.541
Cefazolin 7/22 (32) 8/40 (20) 0.298
Cefuroxime 16/20 (80) 23/29 (79) 1.000
Cefmetazole 8/15 (53) 15/26 (58) 0.956
Ceftriaxone 20/22 (91) 35/44 (88) 1.000
Ceftazidime 12/13 (92) 18/19 (95) 1.000
Cefpirome 16/16 (100) 26/26 (100) 1.000
Aztreonam 15/15 (100) 23/24 (96) 1.000
Piperacillin/tazobactam 11/12 (92) 27/28 (96) 1.000
Imipenem 21/22 (95) 38/40 (95) 1.000
Ciproﬂoxacin 20/20 (100) 35/37 (95) 0.536
Abbreviation: n/N¼Number of Aeromonas isolates susceptible to the antibiotic/
number of Aeromonas isolates available for susceptibility testing.12 of the 28 cancer patients in the present study had abdominal
surgery, eight had received antineoplastic therapy, two had
received radiotherapy and six had septicemia shortly before AIPMB
occurred.
Cirrhosis plays an important role in the pathogenesis of AIPMB
as it leads to many alterations in the immune system, including
decreased reticuloendothelial phagocytic activity, deﬁcient ascetic
ﬂuid opsonic activity and qualitative neutrophil dysfunction
[27e30]. Cirrhosis-associated portal hypertension could alter
intestinal permeability as a result of intestinal congestion, edema
and local hypoxia [31e36].
In this study, >85% of Aeromonas isolates in both community-
acquired and healthcare-associated AIPMB were susceptible to
gentamicin, amikacin, ceftriaxone, ceftazidime, cefpirome, aztreo-
nam, piperacillin/tazobactam, imipenem and ciproﬂoxacin. The
similarity in antibiotic susceptibility suggests that the bloodstream-
invasive Aeromonas in healthcare-associated infections existed in
the gastrointestinal tracts of affected patients before hospitalization
and were not acquired from the institutional environment [8]. The
difference in concurrent pathogens in AIPMB between healthcare-
associated and community-acquired patients might result from
the alteration of microbes that inhabit the patients’ bowel after
hospitalization [37] and which then invade the bloodstream leading
to the development of bacteremia. Non-Enterobacteriaceae from
hospital environments, such as non-fermentative Gram-negative
bacilli or Gram-positive bacteria, can colonize patients’ gastroin-
testinal tracts while they are hospitalized.
One limitation of this study was that the Aeromonas isolates
could not be identiﬁed to species level, as neither automated
system (i.e., the API-20NE, Vitek II system and BD-Phoenix system)
nor conventional biochemical reactions were ideal for this task.
5. Conclusions
The most common underlying diseases/conditions in patients
with AIPMB were solid tumors, liver cirrhosis and gastric acid
suppressant therapy. Although Enterobacteriaceae were the most
common concurrent pathogens for AIPMB, no signiﬁcant difference
in antibiotic susceptibility was found between Aeromonas isolates
in healthcare-associated and community-acquired AIPMBs.
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